Moffitt Plays Pivotal Role in FDA Approval of Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma

A first-of-its-kind cellular immunotherapy pioneered at Moffitt Cancer Center has received approval from the Food and Drug Administration and is now available for patients with advanced melanoma. Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors.

Adoptive Cell Therapy Plus Checkpoint Inhibitors Show Promise in Non-Small Cell Lung Cancer

Researchers in Moffitt Cancer Center’s Lung Cancer Center of Excellence believe a combination of checkpoint inhibitors with adoptive cell therapy could be the answer for non-small cell lung cancer patients. Results of their investigator-initiated phase 1 clinical trial evaluating the checkpoint inhibitor nivolumab in combination with tumor infiltrating lymphocyte (TIL) therapy was published today in Nature Medicine.

Atlantic Health System Physicians Co-Author 5 Studies, Presented at American Association for Cancer Research (AACR) Annual Meeting

Atlantic Health System Cancer Care physicians are co-authors of five original studies presented at this year’s AACR Annual Meeting, held virtually April 10-15 and May 17-21. The AACR meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers.